Oxsedo® 200 mg — A Smarter Evolution in ED Therapy

Smarter Evolution in ED Therapy
Misk Pharma proudly unveils Oxsedo® 200 mg, an advanced erectile dysfunction (ED) therapy powered by Udenafil, launched through a strategic partnership with the Korean pharmaceutical leader Dong-A Pharmaceutical.

Erectile dysfunction is a prevalent and clinically important men’s health condition with a significant impact on quality of life, affecting millions of men globally, including high prevalence across MENA countries and Jordan, particularly among men over 40, underscoring the importance of effective and sustainable treatment options.

In a therapeutic area that has seen limited innovation for more than two decades, Oxsedo® represents a meaningful evolution within the PDE-5 inhibitor class. Udenafil is distinguished by its rapid onset of action, sustained therapeutic window, and improved tolerability, delivering a balanced and patient-centric treatment experience.

Designed to provide reliable efficacy with fewer treatment-limiting side effects, Oxsedo® supports timely responsiveness, prolonged confidence during intimacy, and improved adherence, aligning closely with real-world patient and physician expectations.

Manufactured to the highest international quality and safety standards, Oxsedo® 200 mg equips healthcare professionals with a next-generation ED option, as Misk Pharma prepares to expand Oxsedo® across key MENA markets and establish it as a leading regional reference in modern ED management.